Brendan Delaney

Brendan Delaney

Auto-generated profile, based on publicly available information

Brendan Delaney

Department of Surgery and Cancer, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RVRobert A Verheij
Robert A Verheij
VCVasa Curcin
Vasa Curcin
BDBrendan C Delaney
Brendan C Delaney
MMMark M McGilchrist
Mark M McGilchrist
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

16 September 2000 in BMJ
Verified
Journal Article
Closed access
PDF file
PMPaul Moayyedi
Paul Moayyedi
SSShelly Soo
Shelly Soo
JDJonathan Deeks
Jonathan Deeks
DFDavid Forman
David Forman
JMJames Mason
James Mason
BDBrendan Delaney
Brendan Delaney
Objectives: To evaluate efficacy and cost effectiveness of Helicobacter pylori eradication treatment in patients with non-ulcer dyspepsia infected with H pylori. Design: Systematic review of randomised controlled trials comparing H pylori eradication with placebo or another drug treatment. Results were incorporated into a Markov model comparing health service costs and benefits of H pylori eradication with antacid treatment over one year. Data sources: Six electronic databases were searched for randomised controlled trials from January 1966 to May 2000. Experts in the field, pharmaceutical companies, and journals were contacted for information on any unpublished trials. Trial reports were reviewed according to predefined eligibility and quality criteria. Main outcome measures: Relative risk reduction for remaining dyspeptic symptoms (the same or worse) at 3-12 months. Cost per dyspepsia-free month estimated from Markov model based on estimated relative risk reduction. Results: Twelve trials were included in the systematic review, nine of which evaluated dyspepsia at 3-12 months in 2541 patients. H pylori eradication treatment was significantly superior to placebo in treating non-ulcer dyspepsia (relative risk reduction 9% (95% confidence interval 4% to 14%)), one case of dyspepsia being cured for every 15 people treated. H pylori eradication cost £56 per dyspepsia-free month during first year after treatment. Conclusion: H pylori eradication may be cost effective treatment for non-ulcer dyspepsia in infected patients but further evidence is needed on decision makers' willingness to pay for relief of dyspepsia.

1 November 2004 in Gastroenterology
Verified
Journal Article
Open access
PDF file
PMPaul Moayyedi
Paul Moayyedi
BDBrendan C. Delaney
Brendan C. Delaney
NVNimish Vakil
Nimish Vakil
DFDavid Forman
David Forman
NTNicholas J. Talley
Nicholas J. Talley
Background & Aims: The evidence that proton pump inhibitor (PPI) therapy affects symptoms of nonulcer dyspepsia is conflicting. We conducted a systematic review to evaluate whether PPI therapy had any effect in nonulcer dyspepsia and constructed a health economic model to assess the cost-effectiveness of this approach. Methods: Electronic searches were performed using the Cochrane Controlled Trials Register, MEDLINE, EMBASE, CINAHL, and SIGLE until September 2002. Dyspepsia outcomes were dichotomized into cured/improved versus same/worse. Results were incorporated into a Markov model comparing health service costs and benefits of PPI with antacid therapy over 1 year. Results: Eight trials were identified that compared PPI therapy with placebo in 3293 patients. The relative risk of remaining dyspeptic with PPI therapy versus placebo was .86 (95% confidence interval, .78–.95; P = .003, random-effects model) with a number needed to treat of 9 (95% confidence interval, 5–25). There was statistically significant heterogeneity between trials (heterogeneity χ2 = 30.05; df = 7; P < .001). The PPI strategy would cost an extra $278/month free from dyspepsia if the drug cost $90/month. If a generic price of $19.99 is used, then a PPI strategy costs an extra $57/month free from dyspepsia. A third-party payer would be 95% certain that PPI therapy would be cost-effective, provided they were willing to pay $94/month free from dyspepsia. Conclusions: PPI therapy may be a cost-effective therapy in nonulcer dyspepsia, provided generic prices are used.

1 December 2015 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
MAMohammad Ateya
Mohammad Ateya
BDBrendan C. Delaney
Brendan C. Delaney
SSStuart M. Speedie
Stuart M. Speedie
An increasing number of clinical trials are conducted in primary care settings. Making better use of existing data in the electronic health records to identify eligible subjects can improve efficiency of such studies. Our study aims to quantify the proportion of eligibility criteria that can be addressed with data in electronic health records and to compare the content of eligibility criteria in primary care with previous work. Eligibility criteria were extracted from primary care studies downloaded from the UK Clinical Research Network Study Portfolio. Criteria were broken into elemental statements. Two expert independent raters classified each statement based on whether or not structured data items in the electronic health record can be used to determine if the statement was true for a specific patient. Disagreements in classification were discussed until 100 % agreement was reached. Statements were also classified based on content and the percentages of each category were compared to two similar studies reported in the literature. Eligibility criteria were retrieved from 228 studies and decomposed into 2619 criteria elemental statements. 74 % of the criteria elemental statements were considered likely associated with structured data in an electronic health record. 79 % of the studies had at least 60 % of their criteria statements addressable with structured data likely to be present in an electronic health record. Based on clinical content, most frequent categories were: “disease, symptom, and sign”, “therapy or surgery”, and “medication” (36 %, 13 %, and 10 % of total criteria statements respectively). We also identified new criteria categories related to provider and caregiver attributes (2.6 % and 1 % of total criteria statements respectively). Electronic health records readily contain much of the data needed to assess patients’ eligibility for clinical trials enrollment. Eligibility criteria content categories identified by our study can be incorporated as data elements in electronic health records to facilitate their integration with clinical trial management systems.

7 October 2008 in Family Practice
Verified
Journal Article
Open access
PDF file
OKOlga Kostopoulou
Olga Kostopoulou
BDBrendan C Delaney
Brendan C Delaney
CMCraig W Munro
Craig W Munro
Background. Diagnostic error in primary care can have serious implications for the patient, the clinician and the health-care system, possibly more so than other types of error. Objective. To identify common characteristics of diseases that GPs may misdiagnose. Methods. Systematic search of the MEDLINE and EMBASE databases for primary research on diagnostic error/delay in primary care. Papers on system errors, patient delay, case reports, reviews, opinion pieces, studies not based on actual cases and studies not using a systematic sample were excluded from the review. Twenty-one papers were included. All papers were assessed for quality using the GRADE system. Common features were identified across diseases and presentations that made diagnosis difficult and led to error/delay. Results. Most studies were retrospective cohorts of patients recruited in hospital and collected data from patient interviews and/or hospital records, resulting in incomplete and potentially biased information. It was usually not possible to determine preventability of the delay. Some conditions were extremely rare, suggesting a specialist research interest rather than an increased rate of misdiagnosis. Conditions investigated were malignancies, myocardial infarction, meningitis, dementia, iron deficiency anaemia, asthma, tremor in the elderly and HIV. Common features of difficulty were atypical presentations, non-specific presentations, very low prevalence, the presence of co-morbidity and perceptual features and could be missed. Conclusions. Misdiagnosis in primary care covers a wide range of conditions that may be related in the manner in which they present. The challenge is to identify ways of supporting the diagnostic process in potentially difficult presentations.

1 December 2007 in Health Technology Assessment
Verified
Journal Article
Open access
PDF file
GLG Leontiadis
G Leontiadis
ASA Sreedharan
A Sreedharan
SDS Dorward
S Dorward
PBP Barton
P Barton
BDB Delaney
B Delaney
DFD Forman
D Forman
Health Technology Assessment Volume: 11, Issue: 51, Published in November 2007